Ask the Experts: All Questions

Ask the Experts is one of our most popular destinations for healthcare professionals. Our experts provide clear, easy-to-understand answers to commonly asked questions about vaccines and their use.

How to Find Your Answer

Note: Selecting a filter subcategory may also return results from the primary category. We are working with our vendor to resolve this error.

  • Some filter options may become disabled as you narrow your selections.
  • Filters are easily added and removed. Click or tap on the X to remove individual filters or choose “Reset All Filters” to remove all filters.
Results (1379)

There are many excellent websites that have information about vaccine safety, including the American Academy of Pediatrics, the CDC, Vaccinate Your Family, Immunize.org, the National Academies of Science, Engineering, and Medicine, and the Vaccine Education Center of the Children’s Hospital of Philadelphia.

Last reviewed: August 31, 2022

With some exceptions, there aren’t VISs for combination vaccines. Instead, providers should provide a separate VIS for each vaccine component in the combination (e.g., DTaP-IPV-HepB or DTaP-IPV/Hib). There is a combined VIS (the multi-vaccine VIS) that can substitute for any or all of the routine vaccines given from birth–6 months (DTaP, IPV, Hib, PCV and HepB vaccines). VISs in English and many other languages are available at www.immunize.org/vis/.

Last reviewed: July 15, 2023

Immunity to one of the serotypes of polio does not produce significant immunity to the other serotypes. A history of having recovered from polio disease should not be considered evidence of immunity to polio. You should complete a primary series of IPV if he is known or suspected to have been unvaccinated or incompletely vaccinated against polio. If he received a primary series in childhood, a single adult booster dose may be given before travel to an area where polio vaccination is recommended.

Last reviewed: July 23, 2023

Two vaccines containing varicella virus are licensed for use in the United States. Both vaccines contain live, attenuated varicella zoster virus (VZV) derived from the Oka strain.

  • Varivax (VAR, Merck) contains only varicella vaccine virus.
  • ProQuad (MMRV, Merck) is a combination measles, mumps, rubella, and varicella vaccine

Both vaccines may be administered either by subcutaneous injection or intramuscular injection. VAR is approved by the Food and Drug Administration (FDA) for people 12 months of age and older. MMRV is approved for people 12 months through 12 years of age. MMRV should not be administered to people age 13 years or older.

Last reviewed: May 16, 2023

In infected people, HAV replicates in the liver, is excreted in bile, and is shed in stool. Peak infectivity occurs during the 2-week period before onset of jaundice or elevation of liver enzymes, when concentration of virus in stool is highest. Concentration of virus in stool declines after jaundice appears, with most people no longer infectious about a week after jaundice appears. Children can shed HAV for longer periods than adults, up to 10 weeks or longer after onset of clinical illness.

Last reviewed: June 25, 2023

One pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck) and three pneumococcal conjugate vaccines (PCV15 [Vaxneuvance, Merck], PCV20 [Prevnar 20, Pfizer], and PCV21 [Capvaxive, Merck]) are FDA-licensed and recommended by CDC for use in the United States. PCV13 (Prevnar 13, Pfizer) is FDA-licensed and may still be available in some clinics. It is no longer routinely recommended; however, CDC guidance allows for its use as previously recommended in situations where PCV15, PCV20, or PCV21 is indicated but unavailable and the alternative is that the patient would not be vaccinated.

PPSV23 is licensed for age 2 years and older. It was first licensed in 1983. It is an option for use in series with PCV15 for children and adults ages 2 through 64 years with specified risk factors for pneumococcal disease depending on their prior pneumococcal vaccination history. A PCV15 + PPSV23 series also is recommended as an option for pneumococcal disease prevention in adults 50 years and older. Following the 2022 changes to the pneumococcal vaccination schedule for adults, PPSV23 is no longer recommended alone, however PPSV23 is recommended for adults following PCV15 vaccination. It is not recommended for people who have previously received a PCV20 or PCV21 vaccination.

PCV15 is licensed for people age 6 weeks and older. CDC recommends the use of PCV15 as an option for the routine vaccination of children younger than age 5 years and certain children 6 through 18 years who have conditions that put them at high risk of invasive pneumococcal disease. CDC recommends PCV15 in series with PPSV23 as an option for pneumococcal disease prevention in adults age 19 through 49 years who are at increased risk for invasive pneumococcal disease due to behavioral or medical risk factors and for adults age 50 or older. When used in adults, it is always recommended to be used as part of a vaccination series with PPSV23 typically given 1 year later (a minimum interval of 8 weeks may be considered for people with immunocompromising medical conditions, cochlear implant or cerebrospinal fluid leak).

PCV20 is licensed for people age 6 weeks and older. CDC recommends the use of PCV20 as an option for the routine vaccination of children younger than 5 years of age and certain children 6 through 18 years who have conditions that put them at high risk of invasive pneumococcal disease. CDC recommends it as an option for pneumococcal disease prevention in adults age 19 through 49 years who are at increased risk for invasive pneumococcal disease due to behavioral or medical risk factors and for adults age 50 or older. If PCV20 is given, no further pneumococcal vaccination is recommended.

PCV21 was first licensed and recommended for adults in June 2024. CDC recommends the use of PCV21 as a product option for any adult age 19 or older when a PCV vaccine is recommended. It is specifically designed for adults: it does not contain 10 serotypes contained in PCV20; instead, it contains 11 additional serotypes that cause disease in adults. As with PCV20, after it is administered, no further pneumococcal vaccine doses are recommended.

For details of recommendations for these vaccines, see Recommendations for Pneumococcal Vaccines Use in Children and Teens, www.immunize.org/wp-content/uploads/catg.d/p2016.pdf, or Standing Orders for Administering Pneumococcal Vaccines to Adults: www.immunize.org/wp-content/uploads/catg.d/p3075.pdf.

Last reviewed: November 13, 2024

No. Doses of rabies vaccine given in the gluteus should not be counted as valid and should be repeated. If repeating the invalid dose results in an interval between doses more than 3 days longer than the recommended interval, then you should perform a rabies serology 7–14 days after administration of the final dose in the series to ensure an adequate immune response to the series. For more information about rabies serology, see www.cdc.gov/rabies/php/laboratories/diagnostic.html.

Last reviewed: May 14, 2023

Immunize.org has developed several resources that can help patients identify what they may need. These include:

Translations of these handouts are also available in several languages. To access all of Immunize.org’s clinical resources available in languages other than English, visit www.immunize.org/translations/.  All of these clinical resources can be found in the subsection of clinical resources that address adult immunization:  www.immunize.org/clinical/topic/adult-vaccination/.

In addition to these printed pieces, there are several interactive tools on CDC’s website. For children, go to www2a.cdc.gov/vaccines/childquiz/, and for adults, go to www2.cdc.gov/nip/adultImmSched/.

Last reviewed: January 20, 2025

Medicare Part B (which primarily covers medical outpatient care costs) covers four recommended vaccines for all Medicare beneficiaries: COVID-19, hepatitis B (whether or not a risk factor is reported), influenza, and recommended pneumococcal conjugate and pneumococcal polysaccharide vaccines. Medicare Part B does not cover other adult vaccinations (e.g., Tdap) unless they are directly related to the treatment of an injury or direct exposure to a disease, such as anti-rabies treatment or tetanus prevention due to an injury. In the absence of injury or direct exposure, all other vaccines, including zoster, are covered by Medicare Part D.

Medicare Part D plans (outpatient prescription drug insurance) cover the Advisory Committee on Immunization Practices (ACIP) recommended vaccines that Part B does not cover (for example, RSV and zoster). Since early 2023, the Inflation Reduction Act of 2022 has required Medicare Part D plans to cover ACIP-recommended adult vaccinations without a deductible or copay when given by an in-network provider. Medicare Part D coverage also includes ACIP-recommended vaccines recommended for an individual as a result of occupational or travel-related risks. A summary of adult vaccine insurance coverage can be found at www.izsummitpartners.org/content/uploads/NAIIS_Vaccine-insurance-coverage-2024-2025.pdf.

Last reviewed: February 14, 2025

If a provider suspects an invalid vaccination, including those from persons vaccinated outside the U.S., one of two approaches can be taken. Repeating the vaccinations is an acceptable option. Doing so is generally safe and avoids the need to obtain and interpret serologic tests. If avoiding unnecessary injections is desired, judicious use of serologic testing might be helpful in determining which immunizations are needed. This may be particularly helpful in determining tetanus and diphtheria antitoxin levels for children whose records indicate 3 or more doses of DTP or DTaP. This issue is discussed in detail in the CDC’s “General Best Practices for Immunization” chapter titled Special Situations, and summarized in Table 9-1, available at www.cdc.gov/vaccines/hcp/imz-best-practices/special-situations.html.

Last reviewed: February 16, 2025

The most current comprehensive recommendations from the Advisory Committee on Immunization Practices (ACIP) for meningococcal vaccines is available on the MMWR website at www.cdc.gov/mmwr/volumes/69/rr/pdfs/rr6909a1-H.pdf. This document replaces all previously published reports and policy notes.

ACIP recommendations for the use of MenABCWY (Penbraya) were published in the MMWR in April 2024 and are at www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7315a4-H.pdf.

Last reviewed: November 15, 2024

CDC has published the following summary of 2024–25 season routine COVID-19 vaccination recommendations for people age 6 months and older:

  • Children ages 6 months–4 years
    • Unvaccinated: Should receive a multidose initial series with a 2024–2025 mRNA vaccine
    • Previously completed an initial series: Should receive 1 dose of a 2024–2025 mRNA vaccine from the same manufacturer as the initial series*
  • People ages 5–64 years: Should receive 1 dose of an age-appropriate 2024–2025 COVID-19 vaccine†
  • People ages 65 years and older: Should receive 2 doses of any 2024–2025 COVID-19 vaccine, spaced 6 months (minimum interval 2 months) apart‡

*For children ages 6 months–4 years who initiated but did not complete an initial series, consult CDC Table 1, linked below. 

†People ages 12–64 years who are unvaccinated and receive the 2024–2025 Novavax COVID-19 Vaccine for initial vaccination should receive 2 doses of 2024–2025 Novavax COVID-19 Vaccine. 

‡People ages 65 years and older who are unvaccinated and receive Novavax COVID-19 Vaccine for initial vaccination should receive 2 doses of 2024–2025 Novavax COVID-19 Vaccine followed by a third dose of any 2024–2025 COVID-19 vaccine dose 6 months (minimum interval 2 months) after the second dose. 

See CDC Table 1 for complete details of the routine schedule, dose, and dosing intervals for people age 6 months or older: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01. 

Last reviewed: November 16, 2024

The most recent comprehensive Advisory Committee on Immunization Practices (ACIP) recommendations for Hib vaccination were published in 2014 and are available on the CDC website at www.cdc.gov/acip-recs/hcp/vaccine-specific/hib.html. An ACIP update, adding Vaxelis (DTaP-IPV-Hib-HepB, MSP Company) as a preferred Hib-containing option for vaccination of American Indian/Alaska Native children was published in September 2024 and is also available at the link above. Guidance for Hib vaccination is also provided in the annual childhood immunization schedule, available at www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html.

Last reviewed: January 21, 2025

Vaccine efficacy (VE) during clinical trials in multiple countries ranged from 76% to 82%. VE varied by serotype and was highest for DENV-4 (89% point estimate) and lowest for DENV-1 and DENV-2 (67% point estimate). Among study participants ages 9 through 16 years who developed protective antibodies, the vaccine reduced their risk of hospitalization with dengue by 79% and reduced their risk of severe dengue by 84% over the 5-year follow-up period after vaccination. Studies are ongoing to determine how long protection from hospitalization or severe disease may last, but current evidence show protection lasting at least 6 years after the last dose of vaccine.

Last reviewed: January 17, 2025

CDC has published the following summary of 2024–25 season recommendations for people age 6 months and older who are moderately or severely immunocompromised:

  • Unvaccinated: Should receive a multidose initial series with an age-appropriate 2024–2025 COVID-19 vaccine and 1 dose of a 2024–2025 COVID-19 vaccine 6 months (minimum interval 2 months) after completing the initial series
  • Previously completed an initial series: Should receive 2 doses of an age-appropriate 2024–2025 COVID-19 vaccine, spaced 6 months (minimum interval 2 months) apart*
  • May receive additional age-appropriate 2024–2025 COVID-19 vaccine doses based upon clinical judgment, patient preference, and circumstances

*For people ages 6 months and older who are moderately or severely immunocompromised who initiated but did not complete an initial series, consult CDC Table 2, linked below.  

See CDC Table 2 for complete details of the schedule, brands, dose, and dosing intervals for people age 6 months or older who are moderately or severely immunocompromised: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02.  

Last reviewed: November 16, 2024

In June 2023, ACIP recommended that all adults (18 years and older) in the United States who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary 3-dose vaccination series with IPV: 2 doses of IPV administered at an interval of 4–8 weeks; and a third dose should be administered 6–12 months after the second. Previously, ACIP did not recommend IPV vaccination of unvaccinated or incompletely vaccinated adults who lacked a specific increased risk for exposure to polio (e.g., due to travel). Most U.S. adults may be presumed to be vaccinated against polio unless there is a specific reason to believe otherwise (e.g., an adult whose parents were known to have refused vaccinations). Rates of polio vaccination among children in the United States have been extremely high for decades.

Last reviewed: July 23, 2023


2:23

View All Video Questions

Last reviewed: December 6, 2023

CDC recommends that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. In this case, and in other situations where the same brand is recommended for multiple doses, CDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer:

  • Same vaccine not available at the time of the clinic visit
  • Previous dose unknown
  • Person would otherwise not receive a recommended vaccine dose
  • Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

Therefore, it is acceptable to vaccinate these children with the available product. Note that children age 6 months through 4 years who receive a mixed brand primary series will need a total of 3 doses to complete the primary series.  

Last reviewed: November 16, 2024

Individuals with moderate to severe immunocompromise who have completed a primary series should receive one dose of 2024–2025 Formula COVID-19 vaccine this season followed by a second dose 6 months (minimum 2 months) later. Additional doses of 2024–2025 Formula COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. 

The option to receive additional doses is offered because COVID-19 vaccine effectiveness declines most rapidly in people with moderate to severe immunocompromise. Such people also have the highest risk of hospitalization with COVID-19 if infected. Although protection against severe disease is more durable than protection against milder illness, individuals in these groups may benefit from shorter intervals between doses.

Last reviewed: November 16, 2024

In June 2023, ACIP affirmed its longstanding recommendation that adults who received a primary series of trivalent OPV (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults.

The following are examples of vaccinated adults at increased risk of exposure who may receive a single lifetime booster dose of IPV:

  • Travelers who are going to countries where polio is epidemic or endemic (see polio information for travelers at wwwnc.cdc.gov/travel/)
  • Laboratory and healthcare workers who handle specimens that might contain polioviruses
  • Healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus
Last reviewed: July 23, 2023

No. If you turn off the freezer portion of a household-style combination refrigerator/freezer, the refrigerated compartment will not maintain the proper temperature.

Last reviewed: July 26, 2023

The two rotavirus vaccine products differ in composition and schedule of administration. RotaTeq was approved by the Food and Drug Administration (FDA) in 2006. It contains five reassortant rotaviruses developed from human and bovine parent rotavirus strains; 3 doses are given in the series. Rotarix was approved by the FDA in 2008 and contains an attenuated human rotavirus strain; 2 doses are given in the series.

Last reviewed: June 7, 2023

A polysaccharide vaccine is a type of vaccine that is composed of long chains of sugar molecules, called polysaccharides, that resemble the surface of certain serotypes of pneumococcal bacteria in order to help the immune system mount a response.

A conjugate vaccine is a type of vaccine that joins a protein to an antigen (in the case of pneumococcal vaccines, the protein is connected to unique polysaccharides from the surface of each of the pneumococcal serotypes). The protein helps improve the quality of the immune system response to the vaccine compared to the response to an unconjugated polysaccharide.

Last reviewed: November 13, 2024

Recombinant zoster vaccine (RZV, Shingrix, GlaxoSmithKline) was licensed by the Food and Drug Administration (FDA) in October 2017. It is a subunit vaccine that contains recombinant varicella zoster virus (VZV) glycoprotein E in combination with a novel adjuvant (AS01B). Shingrix does not contain live VZV. It is FDA-approved and recommended by the Advisory Committee on Immunization Practices (ACIP) for all people 50 years and older and for adults age 19 years or older who are or will be immunodeficient or immunosuppressed because of disease or therapy. It has not been evaluated and is not approved for the prevention of primary varicella infection. Shingrix is administered as a 2-dose series by the intramuscular route. The second dose should be given 2 to 6 months after the first dose, with a minimum interval of 1 month (4 weeks) between doses.

Zoster vaccine live (ZVL, Zostavax, Merck) is a live attenuated vaccine that was licensed by the FDA in 2006 for adults age 50 and older and recommended by ACIP for people age 60 and older. Zostavax has been unavailable for use in the United States since November 18, 2020.

Last reviewed: March 9, 2022

A “moderate or severe acute illness” is a precaution for administering any vaccine. A mild acute illness (e.g., diarrhea or mild upper-respiratory tract infection) with or without fever is not a precaution, and vaccines may be given. The concern in vaccinating someone with moderate or severe illness is that a fever following the vaccine could complicate management of the concurrent illness – it could be difficult to determine if the fever was from the vaccine or due to the concurrent illness. In deciding whether to vaccinate a patient with moderate or severe illness, the clinician needs to determine if deferring vaccination will increase the patient’s risk of vaccine-preventable diseases, as is the case if the patient is unlikely to return for vaccination or to seek vaccination elsewhere.

Last reviewed: August 29, 2022

No, Dengvaxia does not protect the recipient against yellow fever.

Last reviewed: January 17, 2025

Generally speaking, no. A person with laboratory evidence of resolved hepatitis B infection is considered immune. Vaccination of such individuals is not harmful but is not necessary.

Last reviewed: January 17, 2025

CDC recommends that all travelers to countries affected by wild (WPV) or circulating vaccine-derived poliovirus (cVDPV) be vaccinated fully against polio. Adults who were fully vaccinated during childhood may receive an additional (single) lifetime booster dose of polio vaccine.

WHO recommends that countries affected by wild poliovirus or cVDPV outbreaks require residents and long-term (4 weeks or more) visitors show proof of polio vaccination before leaving the country. These recommendations are regularly reviewed and updated. Visit CDC’s Travelers’ Health site for current details about country-specific requirements (wwwnc.cdc.gov/travel/).

Last reviewed: July 23, 2023

The most recent comprehensive ACIP recommendations for the use of MMR vaccine were published in 2013 and are available at www.cdc.gov/mmwr/pdf/rr/rr6204.pdf. CDC published the ACIP recommendations for the use of Priorix (GSK) brand of MMR vaccine on November 18, 2022, and they are available here: www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7146a1-H.pdf.

There is no difference in recommendations between Priorix and MMRII (Merck) brands of MMR vaccine. Priorix may be used in any situation where MMR vaccination is recommended. Despite minor differences in manufacturing (MMRII contains gelatin, Priorix does not) and approved route of administration (MMRII is approved for subcutaneous or intramuscular injection, Priorix is approved for subcutaneous injection only), the two vaccines may be considered functionally identical and interchangeable.

MMR vaccine is recommended routinely for all children at age 12 through 15 months, with a second dose at age 4 through 6 years. The second dose of MMR can be given as early as 4 weeks (28 days) after the first dose and be counted as a valid dose if both doses were given after the child’s first birthday. The second dose is not a booster, but rather is intended to produce immunity in the small number of people who fail to respond to the first dose.

Adults with no evidence of immunity should get 1 dose of MMR vaccine (evidence of immunity is defined as documented receipt of 1 dose of live measles virus-containing vaccine [or 2 doses, if high risk], laboratory evidence of immunity or laboratory confirmation of disease, or birth before 1957), unless the adult is in a high-risk group. Susceptible high-risk people need 2 doses of vaccine, given 4 weeks apart. High risk people include school-age children, healthcare personnel, international travelers, and students attending post-high school educational institutions.

Live-attenuated measles vaccine became available in the U.S. in 1963. An ineffective, inactivated measles vaccine was also available in the U.S. in 1963–1967. Combined MMR vaccine (MMRII, Merck) was licensed in 1971; Priorix (GSK) MMR vaccine was licensed and recommended in 2022. For people who previously received a dose of measles vaccine in 1963–1967 and are unsure which type of vaccine it was, or are sure it was inactivated measles vaccine, that dose should be considered invalid and the patient revaccinated as age- and risk-appropriate with MMR vaccine. At the discretion of the state public health department, anyone exposed to measles in an outbreak setting can receive an additional dose of MMR vaccine even if they are considered completely vaccinated for their age or risk status.

Last reviewed: June 19, 2023

Yes. TBE is caused by a flavivirus transmitted by ticks in certain regions of Asia and Europe. Most infections are asymptomatic, but it can cause meningitis and encephalitis. In August 2021, the FDA approved a TBE vaccine, Ticovac (by Pfizer), for people age 1 year or older. The dose for people age 16 years and older is 0.5mL, and for children and adolescents up to age 15 years is 0.25mL. The primary vaccination schedule includes 3 doses, and a booster dose can be given if ongoing exposure or re-exposure to TBE virus is expected. TBE vaccines are also available in many countries overseas where TBE virus is present. For more information from CDC about the TBE vaccine, visit www.cdc.gov/tick-borne-encephalitis/hcp/vaccine/index.html.

Last reviewed: August 21, 2023

Nonsexual HPV transmission is theoretically possible but has not been definitively demonstrated. This is mainly because HPV can’t be cultured, and DNA detection from the environment is difficult and likely prone to false negative results.

Last reviewed: March 2, 2024

MenACWY is recommended for these groups:

Routine vaccination of all children and teens, age 11 through 18 years: a single dose at age 11 or 12 years with a booster dose at age 16 years

Routine vaccination of people age 2 months or older at increased risk for meningococcal disease (the primary dosing schedule and booster dose interval varies by age and indication):

  • People with functional or anatomic asplenia
  • People who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor (examples include eculizumab [Soliris] and ravulizumab [Ultomiris])
  • People who have HIV infection
  • People who are at risk during an outbreak caused by a vaccine serogroup
  • People age 2 months and older who reside in or travel to certain countries in sub-Saharan Africa as well as to other countries for which meningococcal vaccine is recommended (e.g., travel to Mecca, Saudi Arabia, for the annual Hajj)
  • Microbiologists who work with meningococcus bacterial isolates in a laboratory
  • First-year college students living in residence halls who are unvaccinated or undervaccinated; these students should receive a dose if they have not had a dose since turning 16 or if it has been more than 5 years since their previous dose
Last reviewed: November 15, 2024

Recent Tdap vaccination does not affect PCR testing. PCR tests are used to detect DNA sequences of the Bordetella pertussis bacterium. PCR tests are very sensitive and could give a false positive result for other reasons. For more information on best practices when performing PCR testing for pertussis see www.cdc.gov/pertussis/php/pcr-bestpractices.

Last reviewed: October 31, 2023

The incidence of hepatitis A in the US increased more than 10-fold from 2015 to 2019, with over 18,800 cases reported to CDC in 2019. The number of reported cases declined by 47% to 9,952 in 2020. This number is an underestimate of the actual number of infections: CDC estimates that about 19,900 cases actually occurred in 2020.

Between 2012 and 2015 the number of reported hepatitis A infections ranged from approximately 1200 to 1800 cases every year. Beginning in 2016, large foodborne outbreaks led to an increase in the number of cases and sustained, large person-to-person outbreaks began, primarily driven by infections among unvaccinated people who use drugs and people experiencing homelessness and their contacts. Since then, persistent person-to-person outbreaks have led to substantial increases in hepatitis A infection, with 37 states reporting almost 45,000 cases over the 7 years between the beginning of the outbreaks in 2016 and June 2023. The rate of new cases has declined substantially since the peak in 2019. More information regarding ongoing multistate outbreaks can be found here: www.cdc.gov/hepatitis/outbreaks/ongoing-hepatitis-a.

Last reviewed: June 25, 2023

In May 2023, FDA licensed two RSV vaccines: RSVPreF3 (Arexvy, GSK) and RSVpreF (Abrysvo, Pfizer). A third RSV vaccine, mRNA RSV (mResvia, Moderna), was licensed by FDA in May 2024. All three vaccines are licensed for the prevention of RSV-associated lower respiratory tract disease (LRTD) in adults 60 age years and older in the United States. Arexvy is also licensed for use in adults age 50 through 59 years who are increased risk of RSV LRTD; however, ACIP has not yet made recommendations for its use in this age group. Only Abrysvo is licensed for use during pregnancy (during 32 through 36 weeks and 6 days’ gestation) for the prevention of RSV disease in infants.

Arexvy and Abrysvo are recombinant protein vaccines that contain the prefusion form of the spike protein found on the surface of the RSV virus. The mResvia mRNA vaccine contains mRNA that encodes the prefusion form of the RSV F glycoprotein. The mRNA vaccine temporarily enables some of the vaccine recipient’s own cells to produce the prefusion form of the spike protein, causing the immune system to respond by generating antibodies to it. Because none of these vaccines contain live virus, they cannot cause RSV illness.

The GSK vaccine, Arexvy, includes an AS01adjuvant, a chemical designed to enhance the immune response to vaccination. AS01 is the same adjuvant used in GSK’s recombinant zoster vaccine (Shingrix), but Arexvy contains half the amount of adjuvant as a dose of Shingrix. Abrysvo and mResvia vaccines do not contain an adjuvant.

For further information about the vaccines, see the FDA package inserts: Arexvy (www.fda.gov/media/167805/download); Abrysvo (www.fda.gov/media/168889/download); and mResvia (www.fda.gov/media/179005/download).

Last reviewed: August 25, 2024

Janssen (Johnson & Johnson) COVID-19 vaccine is no longer available for use in the United States. The last remaining doses expired May 7, 2023. People who received 1 or 2 Janssen COVID-19 Vaccine doses are recommended to receive one 2024–2025 Formula dose (Moderna, Pfizer-BioNTech, or Novavax).

Last reviewed: November 16, 2024

Yearly influenza vaccination continues to be recommended for everyone age 6 months and older. Changes relevant to clinical practice in the CDC’s published ACIP recommendations for influenza vaccination in the 2024-25 season are summarized below:

  • ACIP now recommends high-dose inactivated influenza vaccine (HD-IIV) or adjuvanted inactivated (aIIV) influenza vaccine (each licensed by FDA for people age 65 years or older) as acceptable options for influenza vaccination of solid organ transplant recipients age 18 through 64 years who are on immunosuppressive medication regimens. There is no preference for aIIV or HD-IIV over any other age-appropriate inactivated or recombinant influenza vaccine in this group.
  • The HD-IIV vaccine, which is now trivalent, is given at a dose of 0.5 mL (the previous dose for quadrivalent HD-IIV was 0.7 mL).
  • ACIP affirmed that everyone age 6 months and older who has an egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient’s age and health status may be used. ACIP updated its recommendation to state that egg allergy alone necessitates no additional safety measures for influenza vaccination beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg. All vaccines should be administered in settings in which personnel and equipment needed for rapid recognition and treatment of acute hypersensitivity reactions are available.

The current ACIP recommendations for influenza vaccination are available here:  www.cdc.gov/acip-recs/hcp/vaccine-specific/flu.html.

Last reviewed: August 11, 2024

The accelerated schedule should be used when the child is more than a month behind schedule, until you get them caught up. An accelerated schedule is acceptable as long as minimum ages and minimum intervals are observed for each dose. Once you have the child back on schedule, use the recommended ages and intervals on the childhood schedule. In this case you can give the child the first set of recommended vaccines at age 3 months and then bring him back at age 4 months and give the second set of vaccinations. At this point the child will be caught up and can return to the usual schedule. Be sure to educate the parents and talk to them about the importance of bringing the child back on time.

Last reviewed: June 6, 2023

Syncope, also called fainting, is a temporary loss of consciousness as a result of decreased blood flow to the brain. The most common form of fainting is called “vasovagal” fainting. This type of fainting can be triggered by an event associated with pain or anxiety. Some people may experience jerking movements after fainting which are not seizures. Published literature reveals that about 3% of men and 3.5% of women report at least one episode of fainting during their lifetime.

Last reviewed: August 31, 2022

In May 2022, CDC published updated ACIP recommendations for rabies PrEP based on risk categories. All people in categories 1-4 should receive a 2-dose primary PrEP rabies vaccine series. People in categories 1-3 require additional long-term follow-up with periodic antibody titer checks and/or booster doses, depending on the category. See the table on pages 622-623 of the MMWR publication for details: www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7118a2-H.pdf.

In brief, the risk categories are as follows:

  • Risk category 1: elevated risk of unrecognized or recognized exposures, including unusual or high-risk exposures (e.g., laboratory or rabies vaccine production settings)
  • Risk category 2: elevated risk, exposures typically recognized but may be unrecognized (e.g., people who frequently interact with bats or collect suspected rabies samples)
  • Risk category 3: elevated risk, exposure nearly always recognized (e.g., veterinary workers, people who handle wildlife reservoir species, spelunkers [because of bats], and certain travelers who have increased risk and may have trouble obtaining safe post-exposure prophylaxis)
  • Risk category 4: same type of risk as category 3, but risk period is time-limited (no more than 3 years)
  • Risk category 5: low risk, typical person living in the United States (PrEP not recommended)
Last reviewed: May 14, 2023

Pediarix contains the vaccine components DTaP, IPV, and HepB. The primary series is 3 doses (0.5 mL) given intramuscularly at 2, 4, and 6 months of age. Pediarix is licensed by the Food and Drug Administration (FDA) for only the first 3 doses of the DTaP series. It should not be given to infants younger than 6 weeks of age or to children 7 years or older.

Last reviewed: January 27, 2025

All children, beginning at age 12 months, as well as adults without other evidence of immunity should be vaccinated with 2 doses of varicella vaccine. Special consideration should be given to vaccinating adults who (1) have close contact with people at high risk for severe disease (e.g., healthcare workers and family contacts of immunocompromised people), or (2) are at high risk for exposure or transmission (e.g., teachers of young children; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; non-pregnant women of childbearing age; and international travelers).

Last reviewed: May 16, 2023

All commercial insurance plans compliant with the Affordable Care Act (ACA) should cover vaccines listed on the CDC’s recommended schedules for vaccines for children and adults without any cost-sharing (e.g., no deductible or copay) when given by in-network providers.

The Inflation Reduction Act (IRA) of 2022, which was fully enacted during 2023, substantially reduced cost-related barriers to vaccination for adults. The law eliminated cost-sharing for ACIP-recommended vaccination of all adults covered by traditional Medicaid and Medicaid expansion plans, as well as adults with Medicare Part D.  More information about the ACA and IRA legislation impact on vaccine payment is available in this pdf report published by Avalere on October 2, 2023:  https://avalere.com/wp-content/uploads/2023/10/Guide-to-Vaccine-Coverage-Policies.pdf.

The National Adult and Influenza Immunization Summit (NAIIS) has created a web section with resources on billing and coding for adult vaccinations at www.izsummitpartners.org/naiis-workgroups/access-provider-workgroup/coding-and-billing.

Last reviewed: February 14, 2025

MenB is routinely recommended for these groups:

  • People age 10 years and older who have functional or anatomic asplenia (including sickle cell disease)
  • People age 10 years and older who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor (examples include eculizumab [Soliris], ravulizumab [Ultomiris], and sutimlimab [Sanofi])
  • People age 10 years and older who are exposed during an outbreak caused by serogroup B
  • Microbiologists who work with meningococcal isolates in a laboratory

For adolescents and young adults not otherwise at increased risk for meningococcal B disease, ACIP recommends that a MenB series may be administered to people 16 through 23 years of age (preferred age 16 through 18 years) on the basis of shared clinical decision-making. The shared clinical decision-making recommendation allows the clinician and patient to decide together based upon the risks and benefits of vaccination for the individual patient.

Last reviewed: November 15, 2024

Ideally, you can arrange to have the cast cut to administer vaccines in the anterolateral thighs. If that option is not available, the gluteal region can be used if not covered by the cast. There are no other sites we recommend for vaccination; however, the inactivated polio vaccine could be given subcutaneously in either arm, if the child is large enough. Rotavirus vaccine is given orally and should be administered. If vaccines cannot be given for the 10 weeks, please advise the family to keep people with any illness away from the child until she has been vaccinated. More information see ACIP’s “General Best Practices Guidelines for Immunization”, available at https://www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html.

Last reviewed: December 28, 2022

Three monovalent Hib vaccines are available in the United States: PedvaxHIB (PRP-OMP, Merck), ActHIB (PRP-T, Sanofi) and Hiberix (PRP-T, GSK). These vaccines are composed of Hib purified polyribosylribitol phosphate (PRP) capsular polysaccharide chemically bound (conjugated) to a protein to enhance the quality of the immune response to PRP. All three vaccines are approved for infants in a 3- or 4-dose series (depending on brand).

Two combination vaccines containing Hib are currently available in the United States: Pentacel (DTaP-IPV/Hib, Sanofi) and Vaxelis (DTaP-IPV-Hib-HepB, MSP Company). Pentacel is licensed for use in children younger than age 5 years and contains Hib conjugate, DTaP, and inactivated polio vaccines; it is approved as a 4-dose series for infants at age 2, 4, 6, and 15 through 18 months, but it is not approved for use as the DTaP/IPV booster dose recommended at age 4 to 6 years. Vaxelis (DTaP-IPV-Hib-HepB) is licensed for use in children younger than age 5 years and is FDA-approved and recommended by CDC as a 3-dose primary series of Hib for infants at age 2, 4, and 6 months. Vaxelis is not approved for use as a Hib booster (4th) dose. Vaxelis contains the same PRP-OMP Hib antigen as PedvaxHIB, but in a reduced amount; like PedvaxHIB, it is an ACIP-preferred option for administration to American Indian and Alaska Native infants (who are at increased risk of early-onset invasive Hib disease) because it induces protective antibody levels after the first dose.

Last reviewed: January 21, 2025

There is usually very close agreement between vaccine package inserts and ACIP statements. The Food and Drug Administration (FDA) must approve the package insert and requires documentation for all data and recommendations made in the insert. Occasionally, ACIP may use different data to formulate its recommendations, or try to add flexibility to its recommendations, which results in wording different than in the package insert. ACIP sometimes makes recommendations based on expert opinion and public health considerations. Published recommendations of ACIP should be considered equally as authoritative as those on the package insert.

Last reviewed: January 20, 2025


1:48

View All Video Questions

Last reviewed: May 9, 2023


1:24

View All Video Questions

Last reviewed: March 28, 2023

Vaccines should not be stored in vegetable bins nor in the space occupied by vegetable bins of a household-style refrigerator. This area is commonly closer to the motor of the unit and the temperature is different from that in the body of the refrigerator. We recommend that you remove the vegetable bins and put bottles of water in that space to help maintain a constant temperature in your refrigerator. Vaccines should be placed in the center of the refrigerator, away from the walls and floor of the unit in open containers so air can circulate around the vaccines. If using the refrigerator section of a household-style combination refrigerator/freezer unit, you do not want the top storage shelf in the refrigerator to be too close to the vent that comes from the freezer because this can expose your vaccines to freezing temperatures.

Last reviewed: July 26, 2023

Treatment with antibiotics is not a valid reason to defer vaccination. If the child or adult is otherwise well, or has only a minor illness, vaccines should be administered. But if the person has a moderate or severe acute illness (regardless of antibiotic use) vaccination may be deferred until the person’s condition has improved.

Last reviewed: August 29, 2022

ACIP recommendations and package inserts do not always match. Occasionally, ACIP may use different data to formulate its recommendations, or try to add flexibility to its recommendations (as was the case in this situation), which results in a recommendation different than the package insert. Published recommendations of national advisory groups (such as ACIP or AAP’s Committee on Infectious Diseases) should be considered equally as authoritative as those on the package insert. You should consider 8 months 0 days as the maximum age for a dose of rotavirus vaccine.

Last reviewed: June 7, 2023

In June 2021, ACIP voted to recommend Dengvaxia for routine use in children age 9 through 16 years with laboratory-confirmed previous dengue virus infection and living in areas where CDC has classified dengue as endemic. The recommendation is only for persons with confirmed previous DENV infection because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination.

The vaccine is not approved for use in U.S. travelers who are visiting but not living in an area where dengue is common.

The most current ACIP recommendations for Dengvaxia are available at www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7006a1-H.pdf.

CDC has developed a pre-vaccination checklist for evaluating whether a child should receive Dengvaxia: www.cdc.gov/dengue/resources/DVBD_FS_Vaccination_Checklist-508.pdf.

Last reviewed: January 17, 2025

ACIP does not address this issue. However, CDC recommends that these children should each be vaccinated, notwithstanding they are conjoined. We believe even in conjoined twins who share organs and/or blood supply, vaccination of each child would also be indicated. The rationale is one cannot be sure, even in the latter case, that the common organs/blood supply would eliminate vaccine antigens less quickly, or the immune system(s) would respond adequately, to one dose of each vaccine for the two children. Therefore two doses seems appropriate, that is, one dose of each vaccine for each child.

Last reviewed: December 28, 2022

Shingrix was studied in immunocompetent adults in 2 pre-licensure clinical trials. Efficacy against shingles was 97% for people 50–59 years of age, 97% for people 60–69 years of age, and 91% for people 70 years and older. Among people 70 years and older vaccine efficacy was 85% four years after vaccination.

Vaccine effectiveness (VE) has been evaluated for a limited number of specific immunocompromising conditions. VE estimates vary depending upon the underlying cause of immunocompromise. Studies have estimated VE of 68.2% for autologous hematopoietic cell transplant recipients, and 87.2% and 90.5% for patients with hematologic malignancies and potential immune-mediated diseases, respectively.

Last reviewed: March 9, 2022

HBV is stable in the environment and remains viable for 7 or more days on environmental surfaces at room temperature. HBV can be transmitted despite the absence of visible blood. Any high level disinfectant that is tuberculocidal will inactivate HBV. The Environmental Protection Agency also registers disinfectants specifically approved for use against HIV and HBV; a current list is available at this website: www.epa.gov/pesticide-registration/list-d-epas-registered-antimicrobial-products-effective-against-human-hiv-1.

Last reviewed: January 17, 2025

Yes, although the package inserts states that Pediarix should only be given to infants born to mothers who are HBsAg-negative, ACIP voted in 2003 to expand its recommendations for use to include infants born to women whose HBsAg status is positive or unknown beginning no earlier than age 6 weeks.

Last reviewed: January 27, 2025

In April 2018, the Advisory Committee on Immunization Practices (ACIP) published a compilation of all previous recommendations for the prevention of pertussis, tetanus, and diphtheria (MMWR 2018;678 [RR-2]:1-31). The document can be accessed on the CDC website at www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6702a1-H.pdf.

In January 2020, ACIP published updated Tdap recommendations, stating that either Td or Tdap may be used in situations where Td only was previously recommended. The document can be accessed on the CDC website at www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6903a5-H.pdf.

Last reviewed: March 31, 2022

Healthcare providers (or other covered entities) may share immunization information with schools or daycare facilities, without authorization, if permitted or required by state law. These state laws would not be preempted by the HIPAA Privacy Rule [45 CFR 160.203(c)].

Last reviewed: February 16, 2025

Tick-borne encephalitis (TBE) is a disease caused by a flavivirus transmitted by tick bite in certain areas of Europe and Asia. It may also be transmitted through the consumption of unpasteurized milk or cheese from infected cows, goats, or sheep. CDC provides details of TBE-endemic areas, but notes that the risk of TBE in endemic areas is variable within risk areas and from year-to-year. Additional geographic information is available from CDC: www.cdc.gov/tick-borne-encephalitis/data-maps/.

Travelers moving or traveling to a TBE-endemic area and likely to have extensive exposure to ticks based on their planned outdoor activities and itinerary should be vaccinated for TBE. TBE vaccination may be considered for other travelers to TBE-endemic areas based on their likely exposure to ticks during their activities, their risk of a poor health outcome, and their personal perception and tolerance of risk.

Last reviewed: August 21, 2023
  • If a person is infected with an HPV strain that does not clear (that is, the person becomes persistently infected) the person cannot be reinfected because they are continuously infected.
  • If a person is infected with an HPV strain that clears, some but not all people will have a lower chance of reinfection with the same strain. Data suggest that females are more likely than males to develop immunity after clearance of natural infection.
  • Prior infection with an HPV strain does not lessen the chance of infection with a different HPV strain.
Last reviewed: March 2, 2024

The terminology change from “Category B” to “shared clinical decision-making” was done to describe more clearly the intent of the recommendation that the patient should be informed of the option to be vaccinated against meningococcal serogroup B disease and that the decision to vaccinate against MenB should be made by the provider and patient together. ACA requires coverage of vaccines as indicated on the recommended immunization schedule, including vaccines with shared clinical decision-making recommendations. The Vaccines for Children (VFC) program also covers vaccines recommended for shared clinical decision-making.

Last reviewed: November 15, 2024

The polysaccharide vaccine includes the different polysaccharides (chains of complex sugars) from different serotypes as the antigen. The conjugate vaccines have the polysaccharides for different serotypes attached (or conjugated) to a carrier protein. The immune response to the PPSV23 vaccine is a T-cell independent immune response, while the immune response to PCV vaccination is a T-cell dependent response that produces memory B-cells and reduces carriage of the bacteria in the respiratory track. The PPSV23 does not reduce bacterial carriage.

Last reviewed: November 13, 2024

All three RSV vaccines were effective in preventing RSV-associated lower respiratory tract disease (LRTD) in clinical trial participants, over the course of two RSV seasons.

The global clinical trials for RSVPreF3 (Arexvy, GSK) vaccine involved nearly 25,000 participants and some participants were followed for 2 RSV seasons. One dose reduced the risk of laboratory-confirmed RSV-associated LRTD with two or more symptoms by 82.6% during the first RSV season and 56.1% during the second season.

The RSVpreF (Abrysvo, Pfizer) vaccine global clinical trials involved nearly 37,000 participants, and some participants were followed for 2 RSV seasons. One dose reduced the risk of symptomatic, laboratory-confirmed RSV-associated LRTD with 3 or more symptoms by 88.9% during the first RSV season and 78.6% during a partial second season.

The mRNA RSV (mResvia, Moderna) vaccine global clinical trials involved nearly 37,000 participants. One dose reduced the risk of symptomatic laboratory-confirmed RSV LRTD with three or more symptoms by 80.9% in the first season. After a median follow up time of 18.8 months, its efficacy declined to 48.4%.

Few people enrolled in the clinical trials were either frail or of advanced age (80 or older), and none lived in long-term care facilities. People with immunocompromising conditions were excluded from clinical trials. For this reason, the clinical trials did not measure how well the vaccines would work in the people at highest risk of serious RSV disease.

Last reviewed: August 25, 2024

This page was updated on .

Our Affiliated Sites

For the Public: VaccineInformation.org
For Coalitions: ImmunizationCoalitions.org
65+ Flu Defense
Protect vulnerable, older adult patients from influenza.
Give2MenACWY.org
Improve protection from meningococcal serogroups ACWY.
Mass Vaccination Resources
Access guidance documents, toolkits, and helpful resources.
NAIIS
Home of the National Adult and Influenza Immunization Summit.